29.86
2.48%
-0.77
Genmab ADR stock is currently priced at $29.86, with a 24-hour trading volume of 253.30K.
It has seen a -2.48% decreased in the last 24 hours and a +7.95% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $30.46 pivot point. If it approaches the $29.76 support level, significant changes may occur.
Genmab ADR Stock (GMAB) Financials Data
Genmab ADR (GMAB) Revenue 2023
GMAB reported a revenue (TTM) of $2.39 billion for the quarter ending December 31, 2023, a +17.78% rise year-over-year.
Genmab ADR (GMAB) Net Income 2023
GMAB net income (TTM) was $634.20 million for the quarter ending December 31, 2023, a -16.67% decrease year-over-year.
Genmab ADR (GMAB) Cash Flow 2023
GMAB recorded a free cash flow (TTM) of $1.02 billion for the quarter ending December 31, 2023, a +99.53% increase year-over-year.
Genmab ADR (GMAB) Earnings per Share 2023
GMAB earnings per share (TTM) was $0.9622 for the quarter ending December 31, 2023, a -16.59% decline year-over-year.
Genmab ADR Stock (GMAB) Latest News
Analyst Ratings For Genmab
Benzinga
4 Analysts Assess Genmab: What You Need To Know
Benzinga
Cracking The Code: Understanding Analyst Reviews For Genmab
Benzinga
What's Going On With Danish Healthcare Firm Genmab Stock?
Benzinga
New Strong Buy Stocks for January 17th
Zacks Investment Research
GMAB or TECH: Which Is the Better Value Stock Right Now?
Zacks Investment Research
About Genmab ADR
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.
Cap:
|
Volume (24h):